These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 30022700)
1. Temperature-sensitive liposomes for co-delivery of tamoxifen and imatinib for synergistic breast cancer treatment. Jose A; Ninave KM; Karnam S; Venuganti VVK J Liposome Res; 2019 Jun; 29(2):153-162. PubMed ID: 30022700 [TBL] [Abstract][Full Text] [Related]
2. QbD-based co-loading of paclitaxel and imatinib mesylate by protamine-coated PLGA nanoparticles effective on breast cancer cells. Laxane N; Yadav KS Nanomedicine (Lond); 2024; 19(26):2211-2227. PubMed ID: 38934510 [TBL] [Abstract][Full Text] [Related]
3. Nanohybrid liposomal cerasomes with good physiological stability and rapid temperature responsiveness for high intensity focused ultrasound triggered local chemotherapy of cancer. Liang X; Gao J; Jiang L; Luo J; Jing L; Li X; Jin Y; Dai Z ACS Nano; 2015 Feb; 9(2):1280-93. PubMed ID: 25599568 [TBL] [Abstract][Full Text] [Related]
4. Formulation, characterization, and cellular toxicity assessment of tamoxifen-loaded silk fibroin nanoparticles in breast cancer. Moin A; Wani SUD; Osmani RA; Abu Lila AS; Khafagy ES; Arab HH; Gangadharappa HV; Allam AN Drug Deliv; 2021 Dec; 28(1):1626-1636. PubMed ID: 34328806 [TBL] [Abstract][Full Text] [Related]
5. In vitro effect of imatinib mesylate loaded on polybutylcyanoacrylate nanoparticles on leukemia cell line K562. Hasandoost L; Akbarzadeh A; Attar H; Heydarinasab A Artif Cells Nanomed Biotechnol; 2017 May; 45(3):665-669. PubMed ID: 27133178 [TBL] [Abstract][Full Text] [Related]
6. Polar Lipid Fraction E from Ayesa U; Chong PL Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33182284 [TBL] [Abstract][Full Text] [Related]
7. pH-temperature dual-sensitive nucleolipid-containing stealth liposomes anchored with PEGylated AuNPs for triggering delivery of doxorubicin. García MC; Calderón-Montaño JM; Rueda M; Longhi M; Rabasco AM; López-Lázaro M; Prieto-Dapena F; González-Rodríguez ML Int J Pharm; 2022 May; 619():121691. PubMed ID: 35331830 [TBL] [Abstract][Full Text] [Related]
8. Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting. Ye P; Zhang W; Yang T; Lu Y; Lu M; Gai Y; Ma X; Xiang G Int J Nanomedicine; 2014; 9():2167-78. PubMed ID: 24855354 [TBL] [Abstract][Full Text] [Related]
9. Karpuz M; Ozgenc E; Oner E; Atlihan-Gundogdu E; Burak Z Drug Dev Res; 2024 Feb; 85(1):e22136. PubMed ID: 38009423 [TBL] [Abstract][Full Text] [Related]
10. Co-delivery of doxorubicin and imatinib by pH sensitive cleavable PEGylated nanoliposomes with folate-mediated targeting to overcome multidrug resistance. Chen Y; Cheng Y; Zhao P; Zhang S; Li M; He C; Zhang X; Yang T; Yan R; Ye P; Ma X; Xiang G Int J Pharm; 2018 May; 542(1-2):266-279. PubMed ID: 29551747 [TBL] [Abstract][Full Text] [Related]
11. Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: active ingredient and mediator of drug release. Lindner LH; Hossann M; Vogeser M; Teichert N; Wachholz K; Eibl H; Hiddemann W; Issels RD J Control Release; 2008 Jan; 125(2):112-20. PubMed ID: 18022271 [TBL] [Abstract][Full Text] [Related]
12. Antiproliferative Activity and VEGF Expression Reduction in MCF7 and PC-3 Cancer Cells by Paclitaxel and Imatinib Co-encapsulation in Folate-Targeted Liposomes. Peres-Filho MJ; Dos Santos AP; Nascimento TL; de Ávila RI; Ferreira FS; Valadares MC; Lima EM AAPS PharmSciTech; 2018 Jan; 19(1):201-212. PubMed ID: 28681330 [TBL] [Abstract][Full Text] [Related]
13. Characterization and cytotoxicity studies of DPPC:M(2+) novel delivery system for cisplatin thermosensitivity liposome with improving loading efficiency. Liu H; Zhang Y; Han Y; Zhao S; Wang L; Zhang Z; Wang J; Cheng J Colloids Surf B Biointerfaces; 2015 Jul; 131():12-20. PubMed ID: 25938850 [TBL] [Abstract][Full Text] [Related]
14. Development, characterization and in vitro evaluation of single or co-loaded imatinib mesylate liposomal formulations. Pinto AC; Angelo S; Moreira JN; Simões S J Nanosci Nanotechnol; 2012 Mar; 12(3):2891-900. PubMed ID: 22755139 [TBL] [Abstract][Full Text] [Related]
15. Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma. Liu J; Boonkaew B; Arora J; Mandava SH; Maddox MM; Chava S; Callaghan C; He J; Dash S; John VT; Lee BR J Pharm Sci; 2015 Mar; 104(3):1187-96. PubMed ID: 25573425 [TBL] [Abstract][Full Text] [Related]
16. The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers. Shao M; Sun SL; Li MH; Li BX; Yu H; Shen ZY; Ren YC; Hao ZF; Chang ND; Peng HS; Yang BF J Liposome Res; 2012 Jun; 22(2):168-76. PubMed ID: 22428938 [TBL] [Abstract][Full Text] [Related]
17. Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases. Cosco D; Paolino D; Cilurzo F; Casale F; Fresta M Int J Pharm; 2012 Jan; 422(1-2):229-37. PubMed ID: 22093954 [TBL] [Abstract][Full Text] [Related]
18. Application of Box-Behnken Design in the Preparation, Optimization, and In Vitro Evaluation of Self-Assembly-Based Tamoxifen- and Doxorubicin-Loaded and Dual Drug-Loaded Niosomes for Combinatorial Breast Cancer Treatment. Kulkarni P; Rawtani D J Pharm Sci; 2019 Aug; 108(8):2643-2653. PubMed ID: 30905701 [TBL] [Abstract][Full Text] [Related]
19. Microwave-Triggered Smart Drug Release from Liposomes Co-encapsulating Doxorubicin and Salt for Local Combined Hyperthermia and Chemotherapy of Cancer. Jin Y; Liang X; An Y; Dai Z Bioconjug Chem; 2016 Dec; 27(12):2931-2942. PubMed ID: 27998076 [TBL] [Abstract][Full Text] [Related]
20. Combined Magnetoliposome Formation and Drug Loading in One Step for Efficient Alternating Current-Magnetic Field Remote-Controlled Drug Release. Fortes Brollo ME; Domínguez-Bajo A; Tabero A; Domínguez-Arca V; Gisbert V; Prieto G; Johansson C; Garcia R; Villanueva A; Serrano MC; Morales MDP ACS Appl Mater Interfaces; 2020 Jan; 12(4):4295-4307. PubMed ID: 31904927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]